文献速递类风湿关节炎

羟氯喹与类风湿关节炎中长QT综合征风险:一项随访十九年的退伍军人队列研究

Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen-Year Follow-up.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-01-31

该倾向评分匹配的活性对照安全性研究纳入8,852例新诊断类风湿关节炎退伍军人,比较羟氯喹与其他非生物改善病情抗风湿药。初始2年长QT综合征风险无差异,5年时羟氯喹组风险升高但绝对风险极低,长期随访中风险衰减。

要点

  • 初始2年羟氯喹组LQTS发生4例(0.09%),其他DMARD组5例(0.11%)。
  • 5年时羟氯喹组17例(0.38%)vs 其他DMARD组6例(0.14%),风险高181%。
  • 5年绝对风险差极低,且长期随访中风险衰减。

核心结论

  • 羟氯喹使用在初始2年内与LQTS无关联,此后风险升高并于治疗5年后达显著,但5年绝对风险极低且绝对风险差更低,长期随访中风险衰减。

研究设计与样本

  • 倾向评分匹配的活性对照安全性研究,纳入8,852例新诊断类风湿关节炎退伍军人(平均年龄64±12岁,14%女性,28%黑人)。
  • 4,426例开始羟氯喹,4,426例开始其他非生物DMARD,匹配87项基线特征平衡。
  • 主要结局为随访至2019年12月31日的19年期间LQTS。

主要发现

  • 初始2年LQTS在羟氯喹组4例(0.09%),其他DMARD组5例(0.11%)。
  • 5年发生率羟氯喹组17例(0.38%)vs 其他DMARD组6例(0.14%),羟氯喹组额外11例LQTS事件,需伤害人数403(95%CI 217-1,740),相对风险高181%(95%CI 11%-613%;P=0.030)。
  • 10年总体风险仍显著(HR 2.17;95%CI 1.13-4.18),但第6-10年羟氯喹组仅额外5例LQTS,第11-19年仅额外1例。
  • 与心律失常相关住院或全因死亡无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent evidence suggests that hydroxychloroquine use is not associated with higher 1-year risk of long QT syndrome (LQTS) in patients with rheumatoid arthritis (RA). Less is known about its long-term risk, the examination of which was the objective of this study. METHODS: We conducted a propensity score-matched active-comparator safety study of hydroxychloroquine in 8,852 veterans (mean age 64 ± 12 years, 14% women, 28% Black) with newly diagnosed RA. A total of 4,426 patients started on hydroxychloroquine and 4,426 started on another nonbiologic disease-modifying antirheumatic drug (DMARD) and were balanced on 87 baseline characteristics. The primary outcome was LQTS during 19-year follow-up through December 31, 2019. RESULTS: Incident LQTS occurred in 4 (0.09%) and 5 (0.11%) patients in the hydroxychloroquine and other DMARD groups, respectively, during the first 2 years. Respective 5-year incidences were 17 (0.38%) and 6 (0.14%), representing 11 additional LQTS events in the hydroxychloroquine group (number needed to harm 403; [95% confidence interval (95% CI)], 217-1,740) and a 181% greater relative risk (95% CI 11%-613%; P = 0.030). Although overall 10-year risk remained significant (hazard ratio 2.17; 95% CI 1.13-4.18), only 5 extra LQTS occurred in hydroxychloroquine group over the next 5 years (years 6-10) and 1 over the next 9 years (years 11-19). There was no association with arrhythmia-related hospitalization or all-cause mortality. CONCLUSIONS: Hydroxychloroquine use had no association with LQTS during the first 2 years after initiation of therapy. There was a higher risk thereafter that became significant after 5 years of therapy. However, the 5-year absolute risk was very low, and the absolute risk difference was even lower. Both risks attenuated during longer follow-up. These findings provide evidence for long-term safety of hydroxychloroquine in patients with RA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Quiñones ME, Joseph JK, Dowell S, et al. Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen-Year Follow-up. Arthritis Care Res (Hoboken). 2023. PMID: 36039941. doi:10.1002/acr.25005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。